02.01.2015 Views

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Table 4.8.5 continued<br />

Author<br />

Year<br />

Reference<br />

Country<br />

Study<br />

design<br />

Population<br />

characteristics<br />

Intervention<br />

Method<br />

Number indi<strong>vid</strong>uals<br />

Control<br />

Number<br />

indi<strong>vid</strong>uals<br />

Results<br />

Withdrawal<br />

Drop outs<br />

Study quality<br />

and relevance<br />

Comments<br />

Segers<br />

2006<br />

[43]<br />

The Netherlands<br />

RCT<br />

All pts undergoing<br />

sternotomy in elective<br />

cardio thoracic surgery.<br />

Study period 2 years –<br />

954 pts. 1 200 carciac<br />

operations annually.<br />

Power calculation:<br />

990 pts. Defined<br />

infecitons.<br />

Follow-up 30 days<br />

I: 0.12% chlorhexidine<br />

gluconate solution as oral<br />

rinse and as gel for nasal<br />

application. Oral rinse 10 mL<br />

for 30 seconds. 4 x days. Nose<br />

ointment applied 4 x days in<br />

both nostrils until nasogastric<br />

tube was removed (usually<br />

within 24 h post-op). Nose<br />

cultures taken. Cefuroxime<br />

1.5 g iv 30 min before incision<br />

another dose if op >4 h continued<br />

for 24 h<br />

C: Placebo locally<br />

and iv as above<br />

Overall incidence of<br />

nosocomial infection<br />

I: 96 pts (19.8%)<br />

(116 infections)<br />

C: 123 pts (26.2%)<br />

(164 infections)<br />

ARR 6.4%<br />

(95% CI 1.1–11.7)<br />

p=0.002<br />

LRTI<br />

ARR 6.5%<br />

(95% CI 2.3–10.7)<br />

p=0.002<br />

14 in active<br />

(other ab) and<br />

13 in control<br />

Moderate<br />

Decontamination<br />

of naso- and oropharynx<br />

reduces<br />

infections in cardiac<br />

surgery patients<br />

Deep SSI<br />

ARR 3.2%<br />

(95% CI 0.9–5.5)<br />

p=0.002<br />

Usry<br />

2002<br />

[44]<br />

USA<br />

Prospective<br />

chart study<br />

CABG 1 200 operations/<br />

year<br />

I: Before operation: Intranasal<br />

ointment (mupirocin calcium<br />

2%) 48h and post-op in total<br />

5 days<br />

C: Sternal SSI rates<br />

were compared with<br />

those published by<br />

the Centres for<br />

Disease Control<br />

Superficial sternal<br />

wound infection<br />

I: 1.24% (15/1 205)<br />

C: 2.62% (68/2 595)<br />

Deep sternal<br />

wound infection<br />

I: 0.75% (9/1 205)<br />

C: 1.66% (43/2 595)<br />

94 % had<br />

prophylaxis<br />

Moderate<br />

Historical controls<br />

Vander Salm<br />

1989<br />

[18]<br />

USA<br />

RCT<br />

All pts of 3 surgeons<br />

undergoing heart<br />

surgery with median<br />

sternotomy.<br />

Follow-up 30 days<br />

I: Iv cefazolin (in total 42 pts<br />

with suspected penicillin allergy<br />

vancomycin) for 36 h.<br />

Odd-numbered medical record<br />

= hemostatic mixture + 250 mg<br />

powdered vancomycin<br />

C: Iv cefazolin (in<br />

total 42 pts with<br />

suspected penicillin<br />

allergy vancomycin)<br />

for 36 h. Evennumbered<br />

medical<br />

record=hemostatic<br />

mixture<br />

Sternal wound infection<br />

I: 1 pt (0.45%)<br />

C: 7 pts (3.6%)<br />

p=0.02<br />

Moderate<br />

Antibiotic resistance<br />

not noted<br />

C = Control group; CABG = Coronary artery bypass graft; CI = Confidence interval;<br />

I = Intervention group; iv = Intravenous; h = Hour; LRTI = Lower respiratory tract<br />

infection; OR = Odds ratio; pts = Patients; RCT = Randomised controlled trial<br />

392 antibiotikaprofylax <strong>vid</strong> <strong>kirurgiska</strong> <strong>ingrepp</strong> KAPITEL 4 • den systematiska litteraturöversikten<br />

393

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!